Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia - PubMed (original) (raw)
. 2006 Oct;12(10):1056-64.
doi: 10.1016/j.bbmt.2006.06.004.
Haesook T Kim, Shuli Li, Katherine Stephans, David C Fisher, Corey Cutler, Vincent Ho, Stephanie J Lee, Edgar L Milford, Jerome Ritz, Joseph H Antin, Robert J Soiffer, John G Gribben, Edwin P Alyea
Affiliations
- PMID: 17084369
- DOI: 10.1016/j.bbmt.2006.06.004
Free article
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia
Jennifer R Brown et al. Biol Blood Marrow Transplant. 2006 Oct.
Free article
Abstract
Although chronic lymphocytic leukemia (CLL) remains an incurable disease with standard chemotherapy, the appropriate role and timing of transplantation are unclear. In this analysis, we report the outcomes of 46 patients with advanced CLL who underwent nonmyeloablative stem cell transplantation (NST) from HLA-matched unrelated (67%) or related (33%) donors. Fludarabine (30 mg/m2 x 4) and low-dose intravenous busulfan (0.8 mg/kg/day x 4) were used for conditioning. The 2-year overall survival (OS) and progression-free survival (PFS) rates in this refractory patient population were 54% and 34%, respectively, with a median follow-up of 20 months. The primary cause of treatment failure was relapse, with a 2-year cumulative incidence of 48%. High hematopoietic donor chimerism > or = 75% at day +30 was a significant predictor of 2-year PFS (47% vs 11%; P = .03). In multivariate analysis, chemotherapy-refractory disease at transplantation was associated with a 3.2-fold risk of progression (P = .01) and a 4.6-fold risk of death (P = .02). Increasing number of previous therapies and increasing bone marrow involvement were also associated with decreased PFS and OS. These results suggest that NST using fludarabine and low-dose intravenous busulfan is a reasonable treatment option for patients with advanced CLL, but that NST earlier in the disease course will likely be needed to achieve long-term disease control in a high proportion of patients.
Similar articles
- Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, Ritz J, Antin JH, Soiffer RJ. Alyea EP, et al. Biol Blood Marrow Transplant. 2006 Oct;12(10):1047-55. doi: 10.1016/j.bbmt.2006.06.003. Biol Blood Marrow Transplant. 2006. PMID: 17067911 - Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR; German Cooperative Transplant Study Group. Kröger N, et al. Ann Hematol. 2003 Jun;82(6):336-42. doi: 10.1007/s00277-003-0654-9. Epub 2003 May 1. Ann Hematol. 2003. PMID: 12728337 Clinical Trial. - Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W; Cooperative German Transplant Study Group. Schetelig J, et al. J Clin Oncol. 2003 Jul 15;21(14):2747-53. doi: 10.1200/JCO.2003.12.011. J Clin Oncol. 2003. PMID: 12860954 - Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT. Dreger P, et al. Leukemia. 2003 May;17(5):841-8. doi: 10.1038/sj.leu.2402905. Leukemia. 2003. PMID: 12750695 Review.
Cited by
- Allogeneic transplantation for chronic lymphocytic leukemia.
Laurenti L, Tarnani M, Chiusolo P, Sorà F, Sica S. Laurenti L, et al. Mediterr J Hematol Infect Dis. 2010 Sep 7;2(2):e2010026. doi: 10.4084/MJHID.2010.026. Mediterr J Hematol Infect Dis. 2010. PMID: 21415973 Free PMC article. - Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.
Brown JR, Kim HT, Armand P, Cutler C, Fisher DC, Ho V, Koreth J, Ritz J, Wu C, Antin JH, Soiffer RJ, Gribben JG, Alyea EP. Brown JR, et al. Leukemia. 2013 Feb;27(2):362-9. doi: 10.1038/leu.2012.228. Epub 2012 Aug 14. Leukemia. 2013. PMID: 22955330 Free PMC article. - Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.
Elsawy M, Sorror ML. Elsawy M, et al. Bone Marrow Transplant. 2016 Oct;51(10):1283-1300. doi: 10.1038/bmt.2016.141. Epub 2016 Jun 6. Bone Marrow Transplant. 2016. PMID: 27272454 Review. - Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.
Shaffer BC, Modric M, Stetler-Stevenson M, Arthur DC, Steinberg SM, Liewehr DJ, Fowler DH, Gale RP, Bishop MR, Pavletic SZ. Shaffer BC, et al. Exp Hematol. 2013 Sep;41(9):772-8. doi: 10.1016/j.exphem.2013.04.015. Epub 2013 May 18. Exp Hematol. 2013. PMID: 23689118 Free PMC article. Clinical Trial. - Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.
Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J. Saber W, et al. Blood. 2012 Apr 26;119(17):3908-16. doi: 10.1182/blood-2011-09-381699. Epub 2012 Feb 10. Blood. 2012. PMID: 22327226 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials